

JOB OFFER		
REFERENCE	OPENING DATE	DEADLINE
2021.309	10/06/2024	19/06/2024
PROFILE REQUIREMENTS		
EXCLUSIVE REQUIREMENTS: (1)		
ACADEMIC DEGREE	-Higher Vocational Training in Clinical and Biomedical Laboratories (Justification must be provided with the application).	
EXPERIENCE	-Animal experimentation course (Justification must be provided with the application). -Course of good clinical practices obtained in the last 2 years (Justification must be provided with the application)	
VALUED MERITS / SKYLLS		
EXPERIENCE	<ul style="list-style-type: none"> - Experience in laboratory techniques with biological cultures - Experience in flow cytometry - Experience in molecular biology and proteomics (WB, CMF, ...) - Experience in in vivo studies. 	
CONTRACT INFORMATION		
TYPE OF CONTRACT	EXPECTED INCORPORATION DATE	JOB STATUS
Contract for scientific-technical activities (article 23.bis of Law 14/2011, of June 1, on Science, Technology and Innovation)	June/July	Full time. 1800 hours per year (aprox. 40 h/week)
ANNUAL GROSS SALARY	DURATION OF THE CONTRACT	
20.702,03 € without prejudice to the basic update established in state legislation for 2024.	Indefinite (linked to the duration of the project or to external financing or financing from public grants in full competition).	
WORK LOCATIONS	UNIT/DEPARTMENT	
IDIVAL	Hematologic Neoplasms and Hematopoietic Progenitor Transplantation	
JOB DETAILS		
OFFER DESCRIPTION		
Research support technician		
FUNCTIONS		
Handling and application of techniques related to biological cultures, flow cytometry, molecular biology and proteomics. He will also be able to participate in in vivo experiments.		
PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
Dr. Enrique M. Ocio	Neoplasias Hematológicas Trasplante Progenitores Hematopoyéticos y de	2021. 354: Phase III randomized study comparing bortezomib, lenalidomide, and dexamethasone (VRd) followed by ciltacabtagene autoleucel, a chimeric antigen receptor (T-CAR) T-lymphocyte therapy directed against BCMA vs. bortezomib, lenalidomide and dexamethasone (VRd) followed by lenalidomide and dexamethasone (Rd) therapy in newly diagnosed patients with multiple myeloma for whom hematopoietic stem cell transplantation is not planned as initial treatment.
RECRUITMENT INFORMATION		



SELECTION PROCESS STAGES (2)				EMPLOYMENT EXCHANGE
1. Admission of applications. 2. Competition phase. 3. Interview phase: maximum number of candidates to be interviewed: 3. Minimum score for this phase: 40 4. Report of the Tribunal. 5. Resolution.				NOT
Note: in order for candidates to be considered for recruitment and employment exchange purposes, they must have a total score of at least 30 points.				
SELECTION BOARD				
<ul style="list-style-type: none"> • President: Enrique M. Ocio San Miguel, principal investigator • Member: Patricia Maiso Researcher of the Hemato-oncology group. • Member and secretary: Maria José Marín Vidalled, Coordinator of IDIVAL's Technological Services. 				
VALUATION OF MERITS				
MERITS	EVALUATION	SCORE		MAXIMUM
Experience in laboratory techniques with biological cultures	Curricular	Merit fulfilment	YES/NO	20
Experience in flow cytometry	Curricular	Merit fulfilment	YES/NO	15
Experience in molecular biology and proteomics (WB, CMF, ...)	Curricular	Merit fulfilment	YES/NO	10
Experience in in vivo studies.	Curricular	Merit fulfilment	YES/NO	15
FINAL SCORE				
MAXIMUM TOTAL SCORE BY MERITS				60
MAXIMUM TOTAL SCORE IN INTERVIEW				40
MAXIMUM TOTAL SCORE				100

- (1) Not subsanable
(2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Politica-de-Privacidad

Santander as of the date of electronic signature

Fdo. Francisco Galo Peralta Fernandez

